文献速递血液净化与透析

中国透析预后与实践模式研究中每周两次血液透析与临床结局

Twice-Weekly Hemodialysis and Clinical Outcomes in the China Dialysis Outcomes and Practice Patterns Study.
PubMed 文献 · Kidney Int Rep · 2018-03-17

该研究基于中国DOPPS队列(45个中心,1265例患者),比较每周两次与三次血液透析的生存和住院情况,并按残肾功能分层。结果显示,无论有无残肾功能,每周两次透析与三次透析的调整平均生存时间和住院率均相似(P=0.65),提示每周两次透析在中国主要城市患者中未观察到生存和住院差异。

要点

  • 每周两次透析与三次透析的调整平均生存时间相似(2.20 vs 2.23年,P=0.65)。
  • 住院率在两组间相似,有残肾功能HR 1.15(95%CI 0.66-2.00),无残肾功能HR 1.10(95%CI 0.68-1.79)。
  • 每周两次透析组 normalized protein catabolic rate 较低,提示饮食钠和蛋白限制更严格。

核心结论

  • 在中国主要城市患者中,每周两次与三次血液透析的生存和住院率未见差异,无论有无残肾功能。
  • 研究结果提示需要开展关于减少透析频率并结合营养管理的实用性研究。

研究设计与样本

  • 基于中国DOPPS队列,从3个主要城市各随机选取15个单位(共45个中心),纳入1265例患者。
  • 采用倾向性评分按五分位分层估计生存函数,并拟合比例率模型评估住院率。
  • 所有分析按患者报告的残肾功能(尿量<1杯/天 vs ≥1杯/天)分层。

主要发现

  • 1265例患者中,123例每周两次透析且有残肾功能证据,133例每周两次透析无残肾功能证据。
  • 随访2.5年,调整平均生存时间:有残肾功能者每周两次 vs 三次为2.20 vs 2.23年;无残肾功能者为2.20 vs 2.15年(P=0.65)。
  • 住院率风险比:有残肾功能者每周两次 vs 三次为1.15(95%CI 0.66-2.00),无残肾功能者为1.10(95%CI 0.68-1.79)。
  • 每周两次透析组 normalized protein catabolic rate 较低,透析间期体重增长未明显更高,提示饮食钠和蛋白限制更严格。

临床怎么用

  • 对于中国主要城市的部分血液透析患者,每周两次透析方案在生存和住院方面与每周三次透析相似。
  • 实施每周两次透析时需关注营养管理,包括饮食钠和蛋白限制。

局限性

  • 研究未报告样本量估算或功效计算,可能影响差异检测能力。
  • 残肾功能基于患者报告(尿量<1 vs ≥1杯/天),可能存在信息偏倚。
  • 研究仅纳入中国3个主要城市的45个中心,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In China, a quarter of patients are undergoing 2-times weekly hemodialysis. Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we tested the hypothesis that whereas survival and hospitalizations would be similar in the presence of residual kidney function (RKF), patients without RKF would fare worse on 2-times weekly hemodialysis. METHODS: In our cohort derived from 15 units randomly selected from each of 3 major cities (total N = 45), we generated a propensity score for the probability of dialysis frequency assignment, estimated a survival function by propensity score quintiles, and averaged stratum-specific survival functions to generate mean survival time. We used the proportional rates model to assess hospitalizations. We stratified all analyses by RKF, as reported by patients (urine output <1 vs. ≥1 cup/day). RESULTS: Among 1265 patients, 123 and 133 were undergoing 2-times weekly hemodialysis with and without evidence of RKF. Over 2.5 years, adjusted mean survival times were similar for 2- versus 3-times weekly dialysis groups: 2.20 versus 2.23 and 2.20 versus 2.15 for patients with and without RKF (P = 0.65). Hazard ratios for hospitalization rates were similar for 2- versus 3-times weekly groups, with (1.15, 95% confidence interval = 0.66-2.00) and without (1.10, 95% confidence interval 0.68-1.79]) RKF. The normalized protein catabolic rate was lower and intradialytic weight gain was not substantially higher in the 2- versus 3-times weekly dialysis group, suggesting greater restriction of dietary sodium and protein. CONCLUSION: In our study of patients in China's major cities, we could not detect differences in survival and hospitalization for those undergoing 2- versus 3-times weekly dialysis, regardless of RKF. Our findings indicate the need for pragmatic studies regarding less frequent dialysis with associated nutritional management.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Yan Y, Wang M, Zee J, et al. Twice-Weekly Hemodialysis and Clinical Outcomes in the China Dialysis Outcomes and Practice Patterns Study. Kidney Int Rep. 2018. PMID: 29988994. doi:10.1016/j.ekir.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。